Einige Inhalte dieser Seite sind nur für Abonnenten sichtbar.       Anmelden     oder      Jetzt abonnieren!

Archiv: Unternehmen

Genentech’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer » Report
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer » Report
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss » Report
Roche: Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss » Report
SMG Swiss Marketplace Group Holding AG: SMG announces partial exercise of over-allotment option » Report
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population » Report
Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML » Report
CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis » Report
Cham Swiss Properties AG: ‘Rocket & Tigerli’ construction project: more apartments planned » Report
Cham Swiss Properties AG: Bauvorhaben «Rocket & Tigerli»: Cham Swiss Properties plant mehr Wohnungen » Report
Comet Holding AG: Comet on track after nine months, Q3 results lower amid market uncertainty » Report
Comet Holding AG: Comet auf Kurs nach 9 Monaten, Ergebnisse im dritten Quartal niedriger aufgrund von Marktunsicherheiten » Report
Roche: Genentech Expands Xofluza® Access And Affordability For Upcoming Flu Season With Direct-To-Patient Launch » Report
Amundi - Gold Research » Report
UBS appoints Chief AI Officer to drive its AI strategy » Report
SECO: Konjunkturprognose: US-Zölle belasten Schweizer Industrie, Unsicherheit bleibt hoch » Report
Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025 » Report
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN) » Report
Nestlé S.A.: Nine-month sales 2025: Positive trends; focus on driving growth » Report
Roche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD™, at the ASHG conference 2025 » Report